The meeting focused on three key issues:
1. Election of the new board
2. Amending the term of the new board (Special Resolution attached)
3. Taking stock of AVMI against the backdrop of continental developments with regards to vaccine manufacturing and deliberating the way forward.
1. Election of the new board
2. Amending the term of the new board (Special Resolution attached)
3. Taking stock of AVMI against the backdrop of continental developments with regards to vaccine manufacturing and deliberating the way forward.
The meeting program built on achievements and progress to date, seeking to leverage promising developments on the continent by providing a platform to:
1. Engage key stakeholders from health, science & technology, trade & industry, business, finance and other key African opinion leaders with the aim of strengthening and enhancing local and regional efforts on the continent.
2. Highlight regional and country specific initiatives and identify strategies to take these forward.
3. Address challenges and develop plans to advance and promote African capacity to develop and manufacture vaccines into the future.
1. Engage key stakeholders from health, science & technology, trade & industry, business, finance and other key African opinion leaders with the aim of strengthening and enhancing local and regional efforts on the continent.
2. Highlight regional and country specific initiatives and identify strategies to take these forward.
3. Address challenges and develop plans to advance and promote African capacity to develop and manufacture vaccines into the future.
AVMI moved ahead in its exciting mission of establishing sustainable vaccine manufacturing capacity on the African continent. The AGM aimed to deliver a realistic plan of action with respect to our key objectives i.e. advocacy, partnerships, capacity planning and resource mobilization.
For day one, the first session would provide an overview of AVMI and the VMPA study. Manufacturers based on the African continent would provide progress and achievements from the past years, also the meeting would look at diseases of high importance to the African region. The global health developments would be provided by Wellcome Trust, CEPI and Geoff Banda (University of Edinburgh). AVMI stakeholders such as WHO and HHS would provide a perspective on the vaccine manufacturing platform. These sessions would be followed by a wrap up discussion at the end of the day.
Day two would be a closed meeting as the agenda points would include; the revised Memorandum of Incorporation; election and appointment of key office bearers; the development of an AVMI two-year operational plan and progress.
For day one, the first session would provide an overview of AVMI and the VMPA study. Manufacturers based on the African continent would provide progress and achievements from the past years, also the meeting would look at diseases of high importance to the African region. The global health developments would be provided by Wellcome Trust, CEPI and Geoff Banda (University of Edinburgh). AVMI stakeholders such as WHO and HHS would provide a perspective on the vaccine manufacturing platform. These sessions would be followed by a wrap up discussion at the end of the day.
Day two would be a closed meeting as the agenda points would include; the revised Memorandum of Incorporation; election and appointment of key office bearers; the development of an AVMI two-year operational plan and progress.
| Presentation |
|---|